摘要
目的：探讨比伐芦定应用于急性冠脉综合征（ACS）冠脉介入（PCI）患者30d时的临床疗效。方法：选择2012年2~10月收治的58例12h内出现症状、均接受急诊PCI患者为研究对象,其中36例在PCI实施前应用比伐芦定,40例患者接受普通肝素,两组患者的基线临床特征、冠脉病变情况无差异,普通肝素组使用了更多的血栓抽吸装置（P=0.04）。比较两组主要心脏不良事件发生情况。结果：两组均未有死亡、支架内血栓者。两组30d心力衰竭、因心绞痛再次住院率间差异无统计学意义（P〉0.05）,对照组发生严重出血1例。结论：接受PCI治疗的ACS患者中应用比伐卢定具有更好的安全性。
Objective： To evaluate the efficacy of bivalirudin on ACS treated by PCI in 30 days.Methods： From Feb.2012 to Oct.2012,35 ACS patients underwent PCI assigned to bivalirudin were matched with the other 40 patients receiving unfractioned heparin（UFH）.There were no significantly different in baseline clinical characteristics and angiographic characteristics.UFH group were applied to more glycoprotein IIb/IIIa inhibitors（P=0.02）.30 days rates of bleeding and composite ischemia（death,MI,heart failure,recurrent ischemia） were compared between the two groups.Results： There were no death,MI or stent thrombosis in two groups.30 days heart failure,recurrent ischemia were all similar,but 2 cases of major bleeding was found in UFH group.Conclusion： In contrast with UFH,bivalirudin is more safe for the treatment of ACS patients undergoing PCI.
出处
《中国医药导刊》
2013年第7期1207-1208,共2页
Chinese Journal of Medicinal Guide
关键词
比伐芦定
急性心肌梗死
急诊PCI
Bivalirudin
Acute coronary syndrome
Percutaneous coronary intervention
